Comparison of differences in domestic and overseas listings of Mavacamten

Mavacamten (mavacamten) is the first innovative drug for obstructive hypertrophic cardiomyopathy (oHCM) that targets cardiac myosin, and its launch process has attracted worldwide attention. The original drug Camzyos was approved in the United States in 2022, then the European Union completed marketing authorization in 2023, and China officially approved marketing in 2024, using the trade name "Camzyos/Mafanto". This timeline shows that the gap in the introduction speed of innovative cardiovascular drugs between China and European and American countries is gradually narrowing, and the convergence of regulatory pathways allows domestic patients to have faster access to the world's latest treatments.

After being launched in the United States,Camzyos strictly manages cardiac function with the REMS monitoring system and emphasizes regular ultrasound examinations to reduce the risk of excessive suppression of cardiac function. The European Union followed similar safety monitoring requirements at the time of approval and remained consistent on the indication, i.e., adults with NYHA class II–III oHCM. China's marketing information is highly consistent with Europe and the United States, indicating that regulatory authorities have clearly recognized the clinical value and safety of the drug.

In terms of generic drugs, alternative versions appeared in overseas markets earlier than in China, such as LuciMava launched by Lucius Pharmaceuticals in Laos The dosage form and content are basically the same as the original drugs, making it an important choice for some countries to reduce drug costs. Since the production of generic drugs is under the local regulatory system and focuses on drug consistency evaluation, the ingredients and mechanisms of action are usually highly close to the original drugs. In contrast, China currently relies on original drugs as the main market players and has not introduced overseas generic versions on a large scale. However, it is worth noting that this drug has been included in the national medical insurance and the price is still at an unstable stage.

Taken together, the differences in the launch of Mavacitai in different markets around the world are mainly reflected in three aspects: launch time, price system and the existence of generic drugs. However, its indications, drug mechanisms and monitoring requirements are highly consistent internationally, demonstrating its globally unified value as an innovative treatment for oHCM.

Reference materials:https://bnf.nice.org.uk/drugs/mavacamten/